Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report.
AERD
Asthma
Eosinophilic
Gastroenteritis
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
02
2020
accepted:
03
04
2020
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent. This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives.
Sections du résumé
BACKGROUND
BACKGROUND
Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma.
CASE PRESENTATION
METHODS
We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent.
CONCLUSIONS
CONCLUSIONS
This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives.
Identifiants
pubmed: 32336975
doi: 10.1186/s13223-020-00423-3
pii: 423
pmc: PMC7178951
doi:
Types de publication
Case Reports
Langues
eng
Pagination
27Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsI declare that I haven’t competing interests.
Références
Int J Clin Pharmacol Ther. 2015 Dec;53(12):1015-27
pubmed: 26445140
Ann Allergy Asthma Immunol. 2018 Dec;121(6):742-743
pubmed: 30056148
Epigenomics. 2017 Apr;9(4):539-571
pubmed: 28322581
Pulm Pharmacol Ther. 2019 Feb;54:87-89
pubmed: 30597278
Eur Ann Allergy Clin Immunol. 2019 Sep 16;51(5):213-221
pubmed: 30983308
J Allergy Clin Immunol Pract. 2019 Mar;7(3):1076-1077
pubmed: 30172017
Allergy. 2017 Oct;72(10):1532-1539
pubmed: 28474352
Curr Gastroenterol Rep. 2018 Jul 2;20(8):37
pubmed: 29968127
Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):247-254
pubmed: 28590311